However, in the past decade, there have been new diagnostic approaches such as the amyloid PET, CSF (cerebrospinal fluid) biomarkers and tau and plasma tests, which have been used in the clinical diagnosis of Alzheimer's disease. This evidence concerns the gene MAPT and Alzheimer disease.